147 related articles for article (PubMed ID: 8182921)
21. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype.
Berman E; Adams M; Duigou-Osterndorf R; Godfrey L; Clarkson B; Andreeff M
Blood; 1991 Feb; 77(4):818-25. PubMed ID: 1993221
[TBL] [Abstract][Full Text] [Related]
22. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
Bogush T; Robert J
Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of induction chemotherapy with daunorubicin or idarubicin in the treatment of an adult with acute lymphoblastic leukemia.
Zhang Q; Zhang CH; Wang ZD; Wang D
Tumori; 2022 Apr; 108(2):182-188. PubMed ID: 34296648
[TBL] [Abstract][Full Text] [Related]
24. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.
Mandelli F; Petti MC; Ardia A; Di Pietro N; Di Raimondo F; Ganzina F; Falconi E; Geraci E; Ladogana S; Latagliata R
Eur J Cancer; 1991; 27(6):750-5. PubMed ID: 1829918
[TBL] [Abstract][Full Text] [Related]
25. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; Fleischhack G; Graf N; Klingebiel T; Kremens B; Lehrnbecher T; von Neuhoff C; Ritter J; Sander A; Schrauder A; von Stackelberg A; Starý J; Reinhardt D
Blood; 2013 Jul; 122(1):37-43. PubMed ID: 23704089
[TBL] [Abstract][Full Text] [Related]
26. Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs.
Nagasawa K; Ohnishi N; Yokoyama T
Jpn J Cancer Res; 1997 Aug; 88(8):750-9. PubMed ID: 9330607
[TBL] [Abstract][Full Text] [Related]
27. Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.
Adige S; Lapidus RG; Carter-Cooper BA; Duffy A; Patzke C; Law JY; Baer MR; Ambulos NP; Zou Y; Bentzen SM; Emadi A
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1105-1112. PubMed ID: 30968179
[TBL] [Abstract][Full Text] [Related]
28. Flow cytometric monitoring of anthracycline accumulation after anti-neoplastic ether phospholipid treatment.
Principe P; Faussat-Suberville AM; Coulomb H; Marie JP; Braquet P
Anticancer Drugs; 1994 Jun; 5(3):329-35. PubMed ID: 7919458
[TBL] [Abstract][Full Text] [Related]
29. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.
Gardin C; Chevret S; Pautas C; Turlure P; Raffoux E; Thomas X; Quesnel B; de Revel T; de Botton S; Gachard N; Renneville A; Boissel N; Preudhomme C; Terré C; Fenaux P; Bordessoule D; Celli-Lebras K; Castaigne S; Dombret H
J Clin Oncol; 2013 Jan; 31(3):321-7. PubMed ID: 23248249
[TBL] [Abstract][Full Text] [Related]
30. Chemomodulation of drugs involved in multidrug resistance in chronic lymphatic leukemia of the B-cell type.
Reichle A; Diddens H; Altmayr F; Rastetter J; Andreesen R
Cancer Chemother Pharmacol; 1994; 34(4):307-16. PubMed ID: 7913420
[TBL] [Abstract][Full Text] [Related]
31. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
[TBL] [Abstract][Full Text] [Related]
32. Effects of verapamil on in vitro intracellular accumulation and retention of daunorubicin in blast cells from patients with acute nonlymphocytic leukemia.
Ross DD; Joneckis CC; Schiffer CA
Blood; 1986 Jul; 68(1):83-8. PubMed ID: 3719105
[TBL] [Abstract][Full Text] [Related]
33. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
Lange BJ; Dinndorf P; Smith FO; Arndt C; Barnard D; Feig S; Feusner J; Seibel N; Weiman M; Aplenc R; Gerbing R; Alonzo TA
J Clin Oncol; 2004 Jan; 22(1):150-6. PubMed ID: 14701777
[TBL] [Abstract][Full Text] [Related]
34. Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines.
Quillet-Mary A; Mansat V; Duchayne E; Come MG; Allouche M; Bailly JD; Bordier C; Laurent G
Leukemia; 1996 Mar; 10(3):417-25. PubMed ID: 8642856
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A.
Nooter K; Sonneveld P; Oostrum R; Herweijer H; Hagenbeek T; Valerio D
Int J Cancer; 1990 Feb; 45(2):263-8. PubMed ID: 1968051
[TBL] [Abstract][Full Text] [Related]
36. P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias.
Damiani D; Michieli M; Ermacora A; Candoni A; Raspadori D; Geromin A; Stocchi R; Grimaz S; Masolini P; Michelutti A; Scheper RJ; Baccarani M
Haematologica; 1998 Apr; 83(4):290-7. PubMed ID: 9592977
[TBL] [Abstract][Full Text] [Related]
37. Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia.
Den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
Leukemia; 1999 Dec; 13(12):2023-30. PubMed ID: 10602424
[TBL] [Abstract][Full Text] [Related]
38. Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.
Eksborg S; Björkholm M; Hast R; Fagerlund E
Anticancer Drugs; 1997 Jan; 8(1):42-7. PubMed ID: 9147610
[TBL] [Abstract][Full Text] [Related]
39. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines.
Bailly JD; Muller C; Jaffrézou JP; Demur C; Gassar G; Bordier C; Laurent G
Leukemia; 1995 May; 9(5):799-807. PubMed ID: 7769842
[TBL] [Abstract][Full Text] [Related]
40. Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
Fukushima T; Inoue H; Takemura H; Kishi S; Yamauchi T; Inai K; Nakayama T; Imamura S; Urasaki Y; Nakamura T; Ueda T
Leuk Res; 1998 Jul; 22(7):625-9. PubMed ID: 9680113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
